Novo Nordisk ends collaboration with Hims & Hers Health, faces competition, lowered fair value

From Morningstar: 2025-06-25 05:01:00

Novo Nordisk ended its collaboration with Hims & Hers Health and shared data on amylin-targeting pipeline therapies at the ADA meeting. Novo aims to increase patient transition to branded Wegovy from compounded semaglutide, but faces competition. Phase 3 data on cagrisema and cagrilintide show promise, but amycretin’s tolerability concerns impact forecasts.

Novo plans to launch oral semaglutide in early 2026, setting a high bar for competitors like Lilly’s orforglipron. Concerns arise over the selectivity of Novo’s amylin-targeting products and potential tolerability issues. Fair value estimate lowered to DKK 552 from DKK 595 due to adjusted sales forecasts and competition factors.



Read more at Morningstar: Novo Nordisk: End to Telehealth Collaboration,…